FDA waves Loxo through for second ‘breakthrough’ in tissue-agnostic cancer therapy

FDA waves Loxo through for second ‘breakthrough’ in tissue-agnostic cancer therapy

Source: 
Endpoints
snippet: 

Three months ago at ASCO, Loxo Oncology wowed the crowd at the big cancer conference with some early-stage data for its second genetically targeted cancer drug candidate. Today, the biotech announced that the FDA seems similarly impressed, offering a breakthrough drug designation to shorten the regulatory timeline just as Loxo has hoped.